A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells

Journal of Controlled Release

Volumn 225, Issue , 2016, Pages 183-191

  Warashina, Shota ^a   Nakamura, Takashi ^a   Sato, Yusuke ^a   Fujiwara, Yuki ^a   Hyodo, Mamoru ^b   Hatakeyama, Hiroto ^c   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b AICHI INSTITUTE OF TECHNOLOGY   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer immunotherapy; Dendritic cell; Dendritic cell based vaccine; Endosomal escape; siRNA nanoparticle; SOCS1

Indexed keywords

CYTOLOGY; DISEASES; EFFICIENCY; GENE THERAPY; GENES; GENETIC ENGINEERING; LIPOSOMES; MAMMALS; NANOPARTICLES; RNA; VECTORS;

CANCER IMMUNOTHERAPY; DENDRITIC CELLS; ENDOSOMAL ESCAPES; LIPOFECTAMINE RNAIMAX; MULTIFUNCTIONAL ENVELOPE-TYPE NANO DEVICES; SMALL INTERFERING RNA (SIRNA); SOCS1; SUPPRESSOR OF CYTOKINE SIGNALING 1;

CELLS;

LIPID; LIPOFECTAMINE; NANOPARTICLE; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG; YSK12 C4 MULTIFUNCTIONAL ENVELOPE TYPE NANO DEVICE; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR B; SOCS1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG SYNTHESIS; FEMALE; GENE SILENCING; GENETIC TRANSDUCTION; IMMUNE RESPONSE; LYMPHOMA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PH; PRIORITY JOURNAL; RNA INTERFERENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; GENE VECTOR; GENETICS; HEMOLYSIS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; HEMOLYSIS; IMMUNOTHERAPY; LIPIDS; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; RNA, SMALL INTERFERING; SCAVENGER RECEPTORS, CLASS B; SUPPRESSOR OF CYTOKINE SIGNALING 1 PROTEIN; TUMOR BURDEN;

EID: 84961330501     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.01.042     Document Type: Article

References (34)

1. S. Anguille, E.L. Smits, E. Lion, V.F. van Tendeloo, and Z.N. Berneman Clinical use of dendritic cells for cancer therapy Lancet Oncol. 15 2014 e257 e267
2. M.L. Huber, L. Haynes, C. Parker, and P. Iversen Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer J. Natl. Cancer Inst. 104 2012 273 279
3. L. Shen, K. Evel-Kabler, R. Strube, and S.Y. Chen Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity Nat. Biotechnol. 22 2004 1546 1553
4. X.T. Song, K. Evel-Kabler, L. Shen, L. Rollins, X.F. Huang, and S.Y. Chen A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression Nat. Med. 14 2008 258 265
5. L. Yang, Y. Pang, and H.L. Moses TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression Trends Immunol. 31 2010 220 227
6. C. Sheridan IDO inhibitors move center stage in immuno-oncology Nat. Biotechnol. 33 2015 321 322
7. J. Jantsch, N. Turza, M. Volke, K.U. Eckardt, M. Hensel, A. Steinkasserer, C. Willam, and A.T. Prechtel Small interfering RNA (siRNA) delivery into murine bone marrow-derived dendritic cells by electroporation J. Immunol. Methods 337 2008 71 77
8. E. Marshall Gene therapy death prompts review of adenovirus vector Science 286 1999 2244 2245
9. X. Gu, J. Xiang, Y. Yao, and Z. Chen Effects of RNA interference on CD80 and CD86 expression in bone marrow-derived murine dendritic cells Scand. J. Immunol. 64 2006 588 594
10. M.H. Karimi, P. Ebadi, A.A. Pourfathollah, Z.S. Soheili, S. Samiee, Z. Ataee, S.Z. Tabei, and S.M. Moazzeni Immune modulation through RNA interference-mediated silencing of CD40 in dendritic cells Cell. Immunol. 259 2009 74 81
11. M.B. Heo, and Y.T. Lim Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells Biomaterials 35 2014 590 600
12. W. Jiang Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice Vaccine 30 2012 758 766
13. Q. Zhang, D.M. Hossain, S. Nechaev, A. Kozlowska, W. Zhang, Y. Liu, C.M. Kowolik, P. Swiderski, J.J. Rossi, S. Forman, S. Pal, R. Bhatia, A. Raubitschek, H. Yu, and M. Kortylewski TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo Blood 121 2013 1304 1315
14. W. Hobo, T.I. Novobrantseva, H. Fredrix, J. Wong, S. Milstein, H. Epstein-Barash, J. Liu, N. Schaap, R. van der Voort, and H. Dolstra Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation Cancer Immunol. Immunother. 62 2013 285 297
15. H. Akita, K. Kogure, R. Moriguchi, Y. Nakamura, T. Higashi, T. Nakamura, S. Serada, M. Fujimoto, T. Naka, S. Futaki, and H. Harashima Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation J. Control. Release 143 2010 311 317
16. S. Warashina, T. Nakamura, and H. Harashima A20 silencing by lipid envelope-type nanoparticles enhances the efficiency of lipopolysaccharide-activated dendritic cells Biol. Pharm. Bull. 34 2011 1348 1351
17. K. Kajimoto, Y. Sato, T. Nakamura, Y. Yamada, and H. Harashima Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo J. Control. Release 190 2014 593 606
18. T. Nakamura, H. Akita, Y. Yamada, H. Hatakeyama, and H. Harashima A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications Acc. Chem. Res. 45 2012 1113 1121
19. K. Kogure, R. Moriguchi, K. Sasaki, M. Ueno, S. Futaki, and H. Harashima Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method J. Control. Release 98 2004 317 323
20. T. Kakudo, S. Chaki, S. Futaki, I. Nakase, K. Akaji, T. Kawakami, K. Maruyama, H. Kamiya, and H. Harashima Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system Biochemistry 43 2004 5618 5628
21. M.B. Lutz, P. Rovere, M.J. Kleijmeer, M. Rescigno, C.U. Assmann, V.M. Oorschot, H.J. Geuze, J. Trucy, D. Demandolx, J. Davoust, and P. Ricciardi-Castagnoli Intracellular routes and selective retention of antigens in mildly acidic cathepsin D/lysosome-associated membrane protein-1/MHC class II-positive vesicles in immature dendritic cells J. Immunol. 159 1997 3707 3716
22. K. Honda, Y. Ohba, H. Yanai, H. Negishi, T. Mizutani, A. Takaoka, C. Taya, and T. Taniguchi Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction Nature 434 2005 1035 1040
23. Y. Sato, H. Hatakeyama, Y. Sakurai, M. Hyodo, H. Akita, and H. Harashima A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo J. Control. Release 163 2012 267 276
24. T. Nakamura, R. Moriguchi, K. Kogure, N. Shastri, and H. Harashima Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes Mol. Ther. 16 2008 1507 1514
25. T. Nakamura, Y. Fujiwara, S. Warashina, and H. Harashima The intracellular pharmacodynamics of siRNA is responsible for the low gene silencing activity of siRNA-loaded nanoparticles in dendritic cells Int. J. Pharm. 494 2015 271 277
26. S. Ramishetti, R. Kedmi, M. Goldsmith, F. Leonard, A.G. Sprague, B. Godin, M. Gozin, P.R. Cullis, D.M. Dykxhoorn, and D. Peer Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles ACS Nano 9 2015 6706 6716
27. S.C. Semple, A. Akinc, J. Chen, A.P. Sandhu, B.L. Mui, C.K. Cho, D.W. Sah, D. Stebbing, E.J. Crosley, E. Yaworski, I.M. Hafez, J.R. Dorkin, J. Qin, K. Lam, K.G. Rajeev, K.F. Wong, L.B. Jeffs, L. Nechev, M.L. Eisenhardt, M. Jayaraman, M. Kazem, M.A. Maier, M. Srinivasulu, M.J. Weinstein, Q. Chen, R. Alvarez, S.A. Barros, S. De, S.K. Klimuk, T. Borland, V. Kosovrasti, W.L. Cantley, Y.K. Tam, M. Manoharan, M.A. Ciufolini, M.A. Tracy, A. de Fougerolles, I. MacLachlan, P.R. Cullis, T.D. Madden, and M.J. Hope Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28 2010 172 176
28. H.A. Chapman Endosomal proteases in antigen presentation Curr. Opin. Immunol. 18 2006 78 84
29. C. Juliana, T. Fernandes-Alnemri, J. Wu, P. Datta, L. Solorzano, J.W. Yu, R. Meng, A.A. Quong, E. Latz, C.P. Scott, and E.S. Alnemri Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome J Biol Chem 285 2010 9792 9802
30. H. Zhang, C. Zhong, L. Shi, Y. Guo, and Z. Fan Granulysin induces cathepsin B release from lysosomes of target tumor cells to attack mitochondria through processing of bid leading to Necroptosis J. Immunol. 182 2009 6993 7000
31. K. Niikura, S. Sekiguchi, T. Nishio, T. Masuda, H. Akita, Y. Matsuo, K. Kogure, H. Harashima, and K. Ijiro Oligosaccharide-mediated nuclear transport of nanoparticles Chembiochem 9 2008 2623 2627
32. S.A. Adam, R.S. Marr, and L. Gerace Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors J. Cell Biol. 111 1990 807 816
33. T. Naka, M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, S. Akira, and T. Kishimoto Structure and function of a new STAT-induced STAT inhibitor Nature 387 1997 924 929
34. A. Yoshimura, T. Naka, and M. Kubo SOCS proteins, cytokine signalling and immune regulation Nat. Rev. Immunol. 7 2007 454 465